Literature DB >> 12065064

Hydromorphone metabolites: isolation and identification from pooled urine samples of a cancer patient.

M Zheng1, K M McErlane, M C Ong.   

Abstract

1. Hydromorphone-3-glucuronide, dihydromorphine, dihydroisomorphine, dihydromorphine-3-glucuronide and dihydroisomorphine-3-glucuronide were isolated from a cancer patient's urine and identified as metabolites of hydromorphone by comparison with synthetic standards using LC/MS/MS with gradient elution. 2. The relative urinary recovery of dihydroisomorphine-3-glucuronide was estimated to be 17-fold higher than previously reported. 3. Three new metabolites, including hydromorphone-3-sulphate, norhydromorphone and nordihydroisomorphine, were tentatively identified.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12065064     DOI: 10.1080/00498250110119090

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  12 in total

Review 1.  Contribution to variability in response to opioids.

Authors:  Geoffrey W Hanks; Colette Reid
Journal:  Support Care Cancer       Date:  2004-12-10       Impact factor: 3.603

2.  Advertisement woes.

Authors:  George Vautour
Journal:  CMAJ       Date:  2005-12-06       Impact factor: 8.262

Review 3.  Role of active metabolites in the use of opioids.

Authors:  Janet K Coller; Lona L Christrup; Andrew A Somogyi
Journal:  Eur J Clin Pharmacol       Date:  2008-10-29       Impact factor: 2.953

Review 4.  Pain Management in Pediatric Chronic Kidney Disease.

Authors:  Amanda Reis; Caitlyn Luecke; Thomas Keefe Davis; Aadil Kakajiwala
Journal:  J Pediatr Pharmacol Ther       Date:  2018 May-Jun

Review 5.  Postoperative analgesia and sedation in the adult intensive care unit: a guide to drug selection.

Authors:  Linda L Liu; Michael A Gropper
Journal:  Drugs       Date:  2003       Impact factor: 9.546

6.  An open-label, 1-year extension study of the long-term safety and efficacy of once-daily OROS(R) hydromorphone in patients with chronic cancer pain.

Authors:  Magdi Hanna; Alberto Tuca; John Thipphawong
Journal:  BMC Palliat Care       Date:  2009-09-15       Impact factor: 3.234

Review 7.  [Differential therapeutic aspects of analgesia with oral sustained-release strong opioids: application intervals, metabolism and immunosuppression].

Authors:  K Güttler; R Sabatowski
Journal:  Schmerz       Date:  2008-10       Impact factor: 1.107

8.  CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes.

Authors:  Mark R Hutchinson; Andrew Menelaou; David J R Foster; Janet K Coller; Andrew A Somogyi
Journal:  Br J Clin Pharmacol       Date:  2004-03       Impact factor: 4.335

9.  Sulfation of opioid drugs by human cytosolic sulfotransferases: metabolic labeling study and enzymatic analysis.

Authors:  Katsuhisa Kurogi; Andriy Chepak; Michael T Hanrahan; Ming-Yih Liu; Yoichi Sakakibara; Masahito Suiko; Ming-Cheh Liu
Journal:  Eur J Pharm Sci       Date:  2014-05-14       Impact factor: 4.384

10.  Recent advances in the use of opioids for cancer pain.

Authors:  Joanne Droney; Julia Riley
Journal:  J Pain Res       Date:  2009-09-23       Impact factor: 3.133

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.